Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILIAD-7 Brazil
NCT04927169Phase 2Terminated
- Sponsor
- RevImmune
- Start
- Mar 2021
- Primary completion
- Dec 2021
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efineptakin alfa in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by RevImmune. Primary endpoint: Change of the absolute lymphocyte count at 30 days. Started Mar 2021; status: terminated.
02
Drugs
efineptakin alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04927169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04927169.